Exagen Inc. (FRA:E08A)

Market Cap	55.03M -17.7%
Revenue (ttm)	56.70M +19.7%
Net Income	-16.99M
EPS	-0.79
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	105
Open	2.260
Previous Close	2.400
Day's Range	2.260 - 2.260
52-Week Range	2.260 - 10.200
Beta	n/a
RSI	41.35
Earnings Date	May 11, 2026

About Exagen

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company’s lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CT...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2002
• Employees: 220
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: E08A

Financial Performance

In 2025, Exagen's revenue was $66.58 million, an increase of 19.65% compared to the previous year's $55.64 million. Losses were -$19.95 million, 32.0% more than in 2024.

Financial numbers in USD